---
title: "Vilon"
canonical_url: https://peptidelibrary.app/library/vilon
description: "Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Vilon

Vilon (also called Lys-Glu or KE dipeptide) is a khavinson dipeptide in the Short Peptide Bioregulator class. Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue.

Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.

Also known as: Lys-Glu, KE dipeptide.

Categories: Longevity, Experimental.

## Classification

- Type: Khavinson dipeptide / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but the work remains largely confined to one research group and Russian-language journals, without independent replication or controlled human trials.

Targets: Immune cells (proposed).

Origin: Synthetic Lys-Glu.

## Properties

- Molecular formula: C11H21N3O5
- Molecular weight: 275.30 g/mol
- CAS number: 37908-74-6
- Half-life: Not established in humans

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 2
- Preclinical sources: 1
- Latest source: 2007

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age. Adv Gerontol. 2006. 2006. Controlled human trial. Population: Patients of different ages with type 1 diabetes. The authors report that Vilon reduced signs of chronic intravascular clotting (DIC syndrome); the effect was smaller in elderly patients with severe disease [Source](https://pubmed.ncbi.nlm.nih.gov/17152731/)
2. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus. Adv Gerontol. 2007. 2007. Human study (early or uncontrolled). Population: Elderly patients with type 1 diabetes. The authors report higher antithrombin III and protein C, more fibrinolysis, shifts in lymphocyte subsets and, in most cases, a lower insulin requirement [Source](https://pubmed.ncbi.nlm.nih.gov/18306698/)
3. Application of peptide bioregulator in complex treatment of elderly cancer patients. Adv Gerontol. 2005. 2005. Controlled human trial. Population: Elderly patients with stage III rectal or colon cancer. Described by the authors as preliminary results suggesting better 2-year survival and fewer complications and recurrences [Source](https://pubmed.ncbi.nlm.nih.gov/16075684/)
4. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004. 2004. Preclinical: in vitro (cells or tissue). Population: Cultured lymphocytes from older people. Unpacking of condensed chromatin and reactivation of ribosomal genes. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/15105581/)

## Safety

Side effects: Not well characterized.

Risks: Research-only.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Vilon is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Vilon?

Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson bioregulator series, studied for immune and geroprotective endpoints. Reported findings include effects on lymphocyte proliferation and on chromatin structure in ageing cells, largely from one research group in Russian-language journals. As a dipeptide its proposed nuclear access is more plausible on size grounds than for longer peptides, but no controlled human trials exist and it is not FDA-approved.

### How does Vilon work?

Vilon is Lys-Glu, a synthetic dipeptide and one of the shortest members of the Khavinson series, associated with thymic and immune tissue. It is among the most cited of the series, with reports that it modulates lymphocyte proliferation, influences chromatin structure and heterochromatin decondensation in ageing lymphocytes, and affects markers used as geroprotective endpoints in rodent studies.

### Is Vilon FDA approved?

No. Vilon is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Vilon?

Reported half-life for Vilon is Not established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to Vilon?

Compounds most often compared with Vilon include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [\[Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age\] — Adv Gerontol, 2006](https://pubmed.ncbi.nlm.nih.gov/17152731/)
- [\[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus\] — Adv Gerontol, 2007](https://pubmed.ncbi.nlm.nih.gov/18306698/)
- [\[Application of peptide bioregulator in complex treatment of elderly cancer patients\] — Adv Gerontol, 2005](https://pubmed.ncbi.nlm.nih.gov/16075684/)
- [Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people — Biogerontology, 2004](https://pubmed.ncbi.nlm.nih.gov/15105581/)
